ArticleBMC pharmacology & toxicology2026
Development and validation of a population pharmacokinetic model for lacosamide in adult patients with epilepsy to inform precision dosing.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Membrane-Dependent Adsorption of Lacosamide in CRRT: Implications for Drug Dosing in Critically Ill Renal Patients.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Prediction of Zonisamide Concentration in Pediatric Patients With Epilepsy: A Machine Learning Approach.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLacosamide is a third-generation antiseizure medication that reduces seizures by promoting slow inactivation of voltage-gated sodium channels. There are significant interindividual differences in the pharmacokinetics of this drug. The aim of this study was to explore the pharmacokinetic characteristics of lacosamide in adult patients with epilepsy and to develop a robust population pharmacokinetic model.
methodsRetrospective data from adult epilepsy patients receiving lacosamide treatment and therapeutic drug monitoring were collected. The population pharmacokinetic model was developed via a nonlinear mixed effects modeling approach. Goodness-of-fit plots (GOF), bootstrap analyses and numerical predictive checks were used to evaluate the final model.
resultsA total of 294 plasma concentrations from 180 patients were included. A one-compartment model with first-order absorption and elimination was employed. In the final population pharmacokinetic model for lacosamide, concomitant use of carbamazepine (CBZ), sex and creatine clearance (CLCR) were covariates of drug clearance (CL/F), which can be expressed via the following equation: CL/F = 1.86 × 1.48CBZ×0.875SEX×(CLCR/119)0.311. The estimation of CL/F was 1.86 L/h. The GOF, bootstrap analysis and numerical predictive check indicated that the model was robust. The simulation indicated that the dose of lacosamide should be increased by 40–60% to achieve the original exposure when it is coadministered with CBZ.
conclusionA population pharmacokinetic model for lacosamide in adult patients with epilepsy was successfully established, which will improve model-based precision medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.